139 related articles for article (PubMed ID: 36782362)
1. Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease modifying antirheumatic drug.
Miyata H; Sonomoto K; Fukuyo S; Nakayamada S; Nakano K; Iwata S; Miyazaki Y; Kawabe A; Aoki T; Tanaka Y
Rheumatology (Oxford); 2023 Oct; 62(10):3339-3349. PubMed ID: 36782362
[TBL] [Abstract][Full Text] [Related]
2. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
[TBL] [Abstract][Full Text] [Related]
3. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
4. Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry.
Jung JY; Lee E; Kim JW; Suh CH; Shin K; Kim J; Kim HA
Arthritis Res Ther; 2023 Sep; 25(1):174. PubMed ID: 37726808
[TBL] [Abstract][Full Text] [Related]
5. Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010.
Ichinose K; Shimizu T; Umeda M; Fukui S; Nishino A; Koga T; Kawashiri SY; Iwamoto N; Tamai M; Nakamura H; Sato S; Origuchi T; Kawakami A
J Immunol Res; 2018; 2018():6259010. PubMed ID: 30186881
[TBL] [Abstract][Full Text] [Related]
6. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs - Analysis of a national claims database.
Sattui SE; Navarro-Millan I; Xie F; Rajan M; Yun H; Curtis JR
Semin Arthritis Rheum; 2022 Dec; 57():152083. PubMed ID: 36155968
[TBL] [Abstract][Full Text] [Related]
7. Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort.
Fujii T; Murata K; Onizawa H; Onishi A; Tanaka M; Murakami K; Nishitani K; Furu M; Watanabe R; Hashimoto M; Ito H; Fujii T; Mimori T; Morinobu A; Matsuda S
Arthritis Res Ther; 2024 Jan; 26(1):16. PubMed ID: 38195572
[TBL] [Abstract][Full Text] [Related]
8. Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study.
Hudson M; Dell'Aniello S; Shen S; Simon TA; Ernst P; Suissa S
Rheumatology (Oxford); 2020 Apr; 59(4):820-827. PubMed ID: 31504972
[TBL] [Abstract][Full Text] [Related]
9. Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
Kalweit M; Burden AM; Boedecker J; Hügle T; Burkard T
PLoS Comput Biol; 2023 Jun; 19(6):e1011073. PubMed ID: 37267387
[TBL] [Abstract][Full Text] [Related]
10. Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010-2019 - a country with a national tender system for prescription of costly drugs.
Brkic A; Diamantopoulos AP; Haavardsholm EA; Fevang BTS; Brekke LK; Loli L; Zettel C; Rødevand E; Bakland G; Mielnik P; Haugeberg G
BMC Health Serv Res; 2022 Jan; 22(1):48. PubMed ID: 35012522
[TBL] [Abstract][Full Text] [Related]
11. A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy.
Wong PKK; Bagga H; Barrett C; Chong G; Hanrahan P; Kodali T; Marabani M; Prince HM; Riordan J; Swarbrick P; White R; Young L
Curr Rheumatol Rep; 2018 Sep; 20(10):64. PubMed ID: 30173305
[TBL] [Abstract][Full Text] [Related]
12. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
13. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia.
Fletcher A; Lassere M; March L; Hill C; Barrett C; Carroll G; Buchbinder R
Rheumatology (Oxford); 2022 Oct; 61(10):3939-3951. PubMed ID: 35094044
[TBL] [Abstract][Full Text] [Related]
14. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
Huss V; Bower H; Wadström H; Frisell T; Askling J;
Rheumatology (Oxford); 2022 May; 61(5):1810-1818. PubMed ID: 34324640
[TBL] [Abstract][Full Text] [Related]
15. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
Cho SK; Lee J; Han M; Bae SC; Sung YK
Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
[TBL] [Abstract][Full Text] [Related]
16. Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook.
Sonomoto K; Tanaka Y
Expert Rev Clin Immunol; 2023; 19(11):1325-1342. PubMed ID: 37578325
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
Baker MC; Liu Y; Lu R; Lin J; Melehani J; Robinson WH
JAMA Netw Open; 2023 Mar; 6(3):e233640. PubMed ID: 36939701
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.
Prawjaeng J; Leelahavarong P; Budtarad N; Pilasant S; Chanjam C; Katchamart W; Narongroeknawin P; Kitumnuaypong T
BMC Health Serv Res; 2023 May; 23(1):561. PubMed ID: 37259090
[TBL] [Abstract][Full Text] [Related]
19. Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis.
McDermott GC; DiIorio M; Kawano Y; Jeffway M; MacVicar M; Dahal K; Moon SJ; Seyok T; Coblyn J; Massarotti E; Weinblatt ME; Weisenfeld D; Liao KP
Semin Arthritis Rheum; 2024 Jun; 66():152421. PubMed ID: 38457949
[TBL] [Abstract][Full Text] [Related]
20. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
